ArticleJournal of oral biology and craniofacial research
Prognostic utility of microRNA-145 and CD 133 in oral squamous cell carcinoma: A pilot study from Northern India.
Article in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential Expression of MicroRNA MiR-145 and MiR-155 Downstream Targets in Oral Cancers Exhibiting Limited Chemotherapy Resistance.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple factors alter the microRNAs (miRNAs) at cellular level and promote oncogenesis in oral mucosa. The present study was performed with an aim to find any expression of miRNA-145 in oral squamous cell carcinoma and correlate it with CD-133 immuno-expression, clinicopathological, and demographical variables in oral squamous cell carcinoma (OSCC) with respect to controls. Materials and methods: In a prospective observational study 50 samples from patients of OSCC and 20 from unremarkable oral mucosa were studied. After initial detailed histology, miRNA-145 profiling was performed using qRT-PCR, followed by CD-133 immunohistochemistry (IHC). Results: The mean age of patients with oral cancer was 47.5 ± 10.25 years. Mean miR-145 levels in OSCC were 0.4312 ± 0.32026 and mean in healthy controls was 0.99 ±0 .21771. There was significant downregulation of miRNA-145 in cases with respect to controls. Significant reduced levels of miRNA-145 with respect to higher clinical tumor size, pathological pT tumor, nodal status, and resultant clinical tumor stage was observed. As far as presence and absence of stem cells was concerned it was seen that tumors displaying presence of stem cells highlighted by CD-133 had lower levels of miRNA-145 as compared to tumors with absent CD-133 staining. Conclusions: miRNA-145 is significantly altered in OSCC in our patient population and its reduced values carry a poor prognosis. Its interaction with CSCs may not be significant but mean miRNA-145 levels are lower in tumors with CSCs. There should be further studies on the larger sample size for these two biomarkers, to know its value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.